Related Experiment Videos
Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin
Mikhail Vaynblat1, Himansu R Shah, Dinesh Bhaskaran
1Division of Cardiovascular Surgery, Department of Surgery, Maimomides Medical Center, Administration Building, Rm D, Department of Surgery, 4802 10th Ave, Brooklyn, NY 11219, USA. mishavayn@aol.com
European Journal of Heart Failure
|November 5, 2002
Summary
Simultaneous enalapril administration significantly improved survival and prevented left ventricular dysfunction in dogs experiencing doxorubicin-induced heart failure. This demonstrates the protective effects of angiotensin converting enzyme (ACE) inhibitors against chemotherapy-related cardiotoxicity.
Area of Science:
- Cardiology
- Pharmacology
- Oncology
Background:
- Doxorubicin is a widely used chemotherapy agent.
- Doxorubicin can cause significant cardiotoxicity, leading to heart failure.
- Preventing doxorubicin-induced cardiomyopathy is crucial for patient care.
Purpose of the Study:
- To investigate the cardioprotective effects of enalapril against doxorubicin-induced heart failure.
- To assess the impact of enalapril on left ventricular dysfunction.
- To evaluate enalapril's efficacy in preventing chemotherapy-induced cardiomyopathy.
Main Methods:
- Seventeen dogs were administered doxorubicin weekly for 4 weeks.
- Animals were divided into two groups: untreated heart failure and simultaneous enalapril administration.
- Hemodynamic data and echocardiography were used to assess cardiac function.
Main Results:
- Survival rate was 100% in the enalapril group versus 36% in the untreated group (P=0.04).
- Enalapril significantly reduced increases in left ventricular end-diastolic pressure and prevented the fall in left ventricular stroke work index.
- Enlargement of the right ventricular end-diastolic diameter was also significantly reduced by enalapril.
Conclusions:
- Simultaneous enalapril treatment is beneficial in preventing doxorubicin-induced cardiomyopathy.
- ACE inhibitors like enalapril show promise in mitigating chemotherapy-related cardiac side effects.
- Enalapril administration can preserve cardiac function during doxorubicin treatment.